LARP6: A Non-Coding RNA Molecule as A Potential Drug Target and Biomarker

Target Name: LARP6

NCBI ID: G55323

LARP6

LARP6: A Non-Coding RNA Molecule as A Potential Drug Target and Biomarker

LARP6 (Long non-coding RNA-protein 6) is a non-coding RNA molecule that has been identified as a potential drug target and biomarker. LARP6 is expressed in a variety of tissues and cells throughout the body and has been shown to play a role in various biological processes, including cell signaling, inflammation, and metabolism.

Drug Target Potential

LARP6 has been identified as a potential drug target due to its involvement in several cellular processes that are associated with various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. LARP6 has been shown to promote the growth and survival of cancer cells, and has been used as a therapeutic target in several studies.

One of the key mechanisms by which LARP6 promotes cancer cell growth and survival is its ability to regulate the cell cycle. LARP6 has been shown to play a role in the regulation of the G1/S transition, which is a critical step in the cell cycle that allows cells to prepare for cell division. By regulating the G1/S transition, LARP6 has been shown to promote the growth and survival of cancer cells.

Another mechanism by which LARP6 promotes cancer cell growth and survival is its ability to regulate cell signaling. LARP6 has been shown to play a role in the regulation of several signaling pathways, including the TGF-β pathway and the Wnt pathway. These signaling pathways are involved in the regulation of cell growth, differentiation, and survival, and have been implicated in the development and progression of many diseases, including cancer.

Biomarker Potential

In addition to its potential as a drug target, LARP6 has also been identified as a potential biomarker for several diseases. For example, LARP6 has been shown to be highly expressed in the brains of individuals with Alzheimer's disease, and has been used as a potential diagnostic biomarker for this disease. LARP6 has also been shown to be highly expressed in the blood vessels of individuals with cardiovascular disease, and has been used as a potential diagnostic biomarker for this disease.

Another potential application of LARP6 as a biomarker is its ability to be used as a target for diagnostic tests. LARP6 has been shown to be highly expressed in a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. This makes it a potential target for diagnostic tests that are designed to detect these diseases, such as cancer biomarkers or autoimmune disease biomarkers.

Conclusion

In conclusion, LARP6 is a non-coding RNA molecule that has been identified as a potential drug target and biomarker. LARP6 is involved in several cellular processes that are associated with various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its ability to regulate the cell cycle and regulate cell signaling makes it a potential drug target, and its high expression in a variety of diseases makes it a potential biomarker. Further research is needed to fully understand the role of LARP6 in these diseases and to develop effective treatments.

Protein Name: La Ribonucleoprotein 6, Translational Regulator

Functions: Regulates the coordinated translation of type I collagen alpha-1 and alpha-2 mRNAs, CO1A1 and CO1A2. Stabilizes mRNAs through high-affinity binding of a stem-loop structure in their 5' UTR. This regulation requires VIM and MYH10 filaments, and the helicase DHX9

The "LARP6 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LARP6 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets